Education
About Us
Working with TipRanks
Follow Us
Palisade Bio, Inc. (PALI)
:PALI
PALI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.53 - $4.32
Previous CloseN/A
Volume307.14K
Average Volume (3M)968.42K
Market Cap
$11.95M
Enterprise Value-$1.81M
Total Cash (Recent Filing)$5.42M
Total Debt (Recent Filing)$24.00K
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Nov 17, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding9,119,152
10 Day Avg. Volume1,841,277
30 Day Avg. Volume968,416
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap-0.15
Enterprise Value/Revenue-453.61
Enterprise Value/Gross Profit1.81K
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$2.00Price Target Upside52.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPalisade announced additional highly positive data from the Phase 1b trial of PALI-2108, showing 100% clinical response in ulcerative colitis patients.
Market PotentialManagement plans to evaluate PALI-2108 specifically for fibrostenotic Crohn’s disease, a large market with no current FDA approved therapies, making it an attractive focus area.
Safety ProfilePALI-2108 was found to be well-tolerated with no serious adverse events, suggesting safety alongside its effectiveness.
Bears Say
Study LimitationsThe data while from a small n-value, is overall directionally positive, supporting the hypothesis that PALI-2108 selectively engages the colon while generating a biologic effect on patients and reducing associated symptoms.
Palisade Bio News
PALI FAQ
What was Palisade Bio, Inc.’s price range in the past 12 months?
Palisade Bio, Inc. lowest stock price was $0.53 and its highest was $4.32 in the past 12 months.
What is Palisade Bio, Inc.’s market cap?
Palisade Bio, Inc.’s market cap is $11.95M.
When is Palisade Bio, Inc.’s upcoming earnings report date?
Palisade Bio, Inc.’s upcoming earnings report date is Nov 17, 2025 which is in 45 days.
How were Palisade Bio, Inc.’s earnings last quarter?
Palisade Bio, Inc. released its earnings results on Aug 19, 2025. The company reported -$0.581 earnings per share for the quarter, beating the consensus estimate of -$0.594 by $0.013.
Is Palisade Bio, Inc. overvalued?
According to Wall Street analysts Palisade Bio, Inc.’s price is currently Undervalued.
Does Palisade Bio, Inc. pay dividends?
Palisade Bio, Inc. does not currently pay dividends.
What is Palisade Bio, Inc.’s EPS estimate?
Palisade Bio, Inc.’s EPS estimate is -0.38.
How many shares outstanding does Palisade Bio, Inc. have?
Palisade Bio, Inc. has 9,119,152 shares outstanding.
What happened to Palisade Bio, Inc.’s price movement after its last earnings report?
Palisade Bio, Inc. reported an EPS of -$0.581 in its last earnings report, beating expectations of -$0.594. Following the earnings report the stock price went down -2.5%.
Which hedge fund is a major shareholder of Palisade Bio, Inc.?
Currently, no hedge funds are holding shares in PALI
Company Description
Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
PALI Stock 12 Month Forecast
Average Price Target
$2.00
▲(52.67% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Quoin Pharmaceuticals
―
Artelo Biosciences
―
Galecto
―
SciSparc Ltd.
―
Ownership Overview
0.24% Insiders
0.32% Mutual Funds
0.30% Other Institutional Investors
99.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---